Loading...

Scott D Christensen

Title(s)Professor, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct; 73(4):645-54. PMID: 26259990.
      View in: PubMed
    2. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015 May 12; 112(10):1644-51. PMID: 25897676.
      View in: PubMed
    3. Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2014 May; 21(5):1616-23. PMID: 24554062.
      View in: PubMed
    4. Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol. 2013 Nov; 72(5):1089-96. PMID: 24057042.
      View in: PubMed
    5. Semrad TJ, Eddings C, Dutia MP, Christensen S, Lara PN. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs. 2013 Jul; 24(6):636-40. PMID: 23698253.
      View in: PubMed
    6. Wasif N, Smith CA, Tamurian RM, Christensen SD, Monjazeb AM, Martinez SR, Canter RJ. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg. 2013 Jul; 148(7):632-9. PMID: 23552630.
      View in: PubMed
    7. Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, Gandara DR, Chen A, Kirkwood JM. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81. PMID: 21880788.
      View in: PubMed
    8. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr; 23(4):1023-9. PMID: 21778300.
      View in: PubMed
    9. Wasif N, Tamurian RM, Christensen S, Do L, Martinez SR, Chen SL, Canter RJ. Influence of specialty and clinical experience on treatment sequencing in the multimodal management of soft tissue extremity sarcoma. Ann Surg Oncol. 2012 Feb; 19(2):504-10. PMID: 21769468.
      View in: PubMed
    10. Heifetz LJ, Christensen SD, Devere-White RW, Meyers FJ. A model for rural oncology. J Oncol Pract. 2011 May; 7(3):168-71. PMID: 21886498.
      View in: PubMed
    11. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. PMID: 20967484.
      View in: PubMed
    12. Martinez SR, Hagge RJ, Christensen SD, Webb JM. Metastatic breast cancer mimicking benign fatty liver infiltration. Breast J. 2008 Jan-Feb; 14(1):108. PMID: 18186875.
      View in: PubMed
    13. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. PMID: 18090584.
      View in: PubMed
    14. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 01; 104(5):1045-8. PMID: 16007689.
      View in: PubMed
    15. Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage. 2004 Dec; 28(6):548-56. PMID: 15589080.
      View in: PubMed
    16. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    17. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. PMID: 11251003.
      View in: PubMed
    18. O'Donnell RT, Leigh BR, Christensen SD, Goldstein DS, Kukis DL, Shen S, Yuan A, DeNardo DA, Kroger LA, DeNardo GL. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. Cancer Biother Radiopharm. 1999 Jun; 14(3):167-76. PMID: 10850301.
      View in: PubMed